Hypersensitivity Pneumonitis Market Size & Share, by Type (Acute, Subacute, Chronic); Treatment (Immunosuppressive, Corticosteroids); End-user (Hospital, Online Pharmacy, Drug Stores, Retail Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5180
  • Published Date: Aug 23, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Hypersensitivity Pneumonitis Market size is poised to reach USD 2 Billion by the end of 2035, growing at a CAGR of 6% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of hypersensitivity pneumonitis was USD 1 Billion. The reason behind the growth is impelled by the increasing prevalence of respiratory diseases across the globe. The third biggest cause of mortality is chronic respiratory conditions caused by risk factors including allergens, occupational dangers, and tobacco use. This has increased awareness regarding such conditions among people, leading to better treatment options for hypersensitivity pneumonitis as well. Each year, asthma accounts for more than 160 000 fatalities worldwide.

The development of non-invasive diagnostic procedures are believed to fuel the hypersensitivity pneumonitis market. Imaging and spirometry are non-invasive techniques used in diagnosis and the measurement of the lung's capacity to inhale and exhale air. For instance, HRCT is a noninvasive, precise diagnostic technology used for the proper diagnosis of chronic hypersensitivity pneumonitis.


Hypersensitivity Pneumonitis Market
Get more information on this report: Request Free Sample PDF

Hypersensitivity Pneumonitis Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Environmental Pollution – It is expected that rise in the release of harmful gases and chemicals into the air is anticipated to drive the growth of hypersensitivity pneumonitis market. Moreover, hypersensitivity pneumonitis is a long illness that is caused by an allergic reaction to certain substances (allergens) inhaled through the air.
    According to estimates, more than 6 million people die from air pollution-related causes worldwide each year.
  • Growing Geriatric Population- Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease (ILD) that is more common among those older than 65 years owing to weekend immune response, and the rising count of older people across the globe is estimated to drive market growth.
    Lately, the number of individuals over 65 in the globe is more than 8% of the population, and this percentage is anticipated to increase to over 15% of the global population by 2050.

Challenges

  • Lack of Awareness – Owing to the absence of sufficient resources in low economic areas people the knowledge about prescription drugs such as corticosteroids is poor. This may impact the market growth as without proper knowledge this medication can be misused.
  • Risk Associated with Underdiagnosis and Misdiagnosis of Hypersensitivity Pneumonitis
  • Side Effects Associated with Long-Term Treatment

Hypersensitivity Pneumonitis Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~6%

Base Year Market Size (2022)

~ USD 1 Billion

Forecast Year Market Size (2035)

~ USD 2 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Hypersensitivity Pneumonitis Segmentation

Treatment (Immunosuppressive, Corticosteroids)

The corticosteroids segment is estimated to account for 60% share of the global hypersensitivity pneumonitis market in the coming years owing to the benefits provided by this treatment. Corticosteroids are considered in patients with severe lung function impairment as both low-dose oral corticosteroids provide adequate initial treatment of acute hypersensitivity pneumonitis.  Corticosteroids improve survival and slow fibrotic progression in a matched cohort and the therapy may accelerate the initial recovery in persons with severe disease. For instance, corticosteroids such as prednisone usually 60 mg orally once a day for 1 to 2 weeks, are prescribed for severe symptoms or significant lung dysfunction.

End-User (Hospital, Online Pharmacy, Drug Stores, Retail Pharmacy)

Hypersensitivity pneumonitis market from the hospital segment is set to garner a notable share shortly on account of growing advancements in diagnostic techniques. Hospitals are equipped with advanced tools for diagnosis of various diseases including hypersensitivity pneumonitis. This may lead to more patients visiting hospitals for managing acute to severe cases of hypersensitivity pneumonitis.

Our in-depth analysis of the global market includes the following segments:

  Type

  • Acute
  • Subacute
  • Chronic

  Treatment

  • Immunosuppressive
  • Corticosteroids

  End-User

  • Hospital
  •  Online Pharmacy
  •  Drug Stores
  •  Retail Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Hypersensitivity Pneumonitis Industry- Regional Synopsis

North American Market Forecast

Hypersensitivity pneumonitis market in North America is predicted to account for the largest share of 37% by 2035 impelled by the increasing spending in healthcare. This would allocate more resources to the healthcare which may improve the diagnostic capabilities and provide access to treatments for people with hypersensitivity pneumonitis.

According to estimates, Healthcare costs in the US are currently rising by over 1% faster than the GDP every year and by 2028 spending on healthcare in the United States will total more than USD 6 trillion.

European Market Statistics

The Europe hypersensitivity pneumonitis market is estimated to be the second largest, during the forecast timeframe led by growing healthcare awareness. Various campaigns and awareness programs are being conducted in the region which has led to an increase in public knowledge about the hypersensitivity pneumonitis disease. As a result, more and more people are being diagnosed with the disease.

Research Nester
Hypersensitivity Pneumonitis Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Hypersensitivity Pneumonitis Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Svizera Healthcare Pvt. Ltd.
    • Sanofi S.A.
    • Novo Nordisk A/S
    • Eli lilly and Company
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Abbott Laboratories Inc.
    • Astra Zeneca Plc.

In-the-news

In The News

  • Pfizer Inc. received approval from the U.S. Food and Drug Administration (FDA) for metastatic non-small cell lung cancer which is the second most common type of cancer in the world.
  • Sanofi S.A. an innovative global healthcare company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Dupixent (dupilumab) a monoclonal antibody used to treat allergic conditions such as, asthma. Further, is the first and only biologic drug authorized for the treatment of moderate-to-severe atopic dermatitis, and the children treated with Dupixent with topical corticosteroids (TCS) reported that they had cleaner skin and considerably less itching.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5180
  • Published Date: Aug 23, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of respiratory diseases across the globe and the development of non-invasive diagnostic procedures are the major factors driving the growth of the market.

The market size of Hypersensitivity Pneumonitis is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Astra Zeneca Plc., Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG.

The corticosteroids segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Hypersensitivity Pneumonitis Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying